Suzanne L Topalian

List of Publications by Year in Descending Order

63 papers	40,668 citations	46 h-index	64 g-index
64 ext. papers	47,157 ext. citations	14.5 avg, IF	7.16 L-index

#	Paper	IF	Citations
63	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. *Clinical Cancer Research*, **2021**, 27, 1516-1525	12.9	2
62	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. *Science*, **2021**, 372,	33.3	25
61	Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial **2021**, 9,		23
60	Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop. *Clinical Cancer Research*, **2021**, 27, 394-401	12.9	3
59	Neoadjuvant checkpoint blockade for cancer immunotherapy. *Science*, **2020**, 367,	33.3	231
58	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce **2020**, 8,		43
57	Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. *Clinical Cancer Research*, **2020**, 26, 545-551	12.9	43
56	Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. *Cell Reports Medicine*, **2020**, 1, 100139	18	17
55	Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. *Cancer Cell*, **2020**, 38, 500-515.e3	24.3	75
54	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. *Journal of Clinical Oncology*, **2020**, 38, 2476-2487	2.2	72
53	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. *JAMA Oncology*, **2019**, 5, 1411-1420	13.4	216
52	Mechanisms regulating PD-L1 expression on tumor and immune cells **2019**, 7, 305		140
51	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. *New England Journal of Medicine*, **2018**, 378, 1976-1986	59.2	865
50	Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy **2018**, 6, 131		29
49	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab **2018**, 6, 99		73
48	Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy. *Clinical Cancer Research*, **2017**, 23, 3168-3180	12.9	51
47	Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. *JAMA Oncology*, **2017**, 3, 974-978	13.4	49

46	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. *Journal of Clinical Oncology*, **2017**, 35, 785-792	2.2	696
45	Targeting Immune Checkpoints in Cancer Therapy. *JAMA - Journal of the American Medical Association*, **2017**, 318, 1647-1648	27.4	83
44	Identification and Characterization of Complex Glycosylated Peptides Presented by the MHC Class II Processing Pathway in Melanoma. *Journal of Proteome Research*, **2017**, 16, 228-237	5.6	25
43	Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy. *Blood Advances*, **2017**, 1, 1324-1334	7.8	24
42	The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. *Cancer Immunology Research*, **2016**, 4, 726-33	12.5	85
41	Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule **2016**, 4, 37		
40	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. *Nature Reviews Cancer*, **2016**, 16, 275-87	31.3	1444
39	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. *New England Journal of Medicine*, **2016**, 374, 2542-52	59.2	828
38	Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. *Clinical Cancer Research*, **2015**, 21, 3969-76	12.9	172
37	Antagonists of PD-1 and PD-L1 in Cancer Treatment. *Seminars in Oncology*, **2015**, 42, 587-600	5.5	206
36	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. *Journal of Clinical Oncology*, **2015**, 33, 2013-20	2.2	337
35	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2015**, 33, 2004-12	2.2	859
34	Immune checkpoint blockade: a common denominator approach to cancer therapy. *Cancer Cell*, **2015**, 27, 450-61	24.3	2410
33	PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. *Cancer Immunology Research*, **2015**, 3, 110-5	12.5	43
32	Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. *Journal of Translational Medicine*, **2015**, 13, 214	8.5	58
31	Balance and imbalance in the immune system: life on the edge. *Immunity*, **2014**, 41, 682-4	32.3	23
30	Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. *Clinical Cancer Research*, **2014**, 20, 5064-74	12.9	1661
29	Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. *Journal of Clinical Oncology*, **2014**, 32, 1020-30	2.2	1684

28	Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. *Cancer Research*, **2013**, 73, 1733-41	10.1	564
27	Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. *Clinical Cancer Research*, **2013**, 19, 462-8	12.9	407
26	Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity. *Journal of Immunology*, **2013**, 191, 5097-106	5.3	18
25	PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. *Cancer Immunology Research*, **2013**, 1, 54-63	12.5	277
24	Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. *Oncotarget*, **2013**, 4, 2067-79	3.3	285
23	Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. *Current Opinion in Immunology*, **2012**, 24, 207-12	7.8	979
22	Structural insights into the editing of germ-line-encoded interactions between T-cell receptor and MHC class II by V□CDR3. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 14960-5	11.5	34
21	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *New England Journal of Medicine*, **2012**, 366, 2443-54	59.2	8684
20	Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *New England Journal of Medicine*, **2012**, 366, 2455-65	59.2	5527
19	Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. *Science Translational Medicine*, **2012** , 4, 127ra37	17.5	1562
18	Cancer immunotherapy comes of age. *Journal of Clinical Oncology*, **2011**, 29, 4828-36	2.2	336
17	Opportunities and challenges in the development of experimental drug combinations for cancer. *Journal of the National Cancer Institute*, **2011**, 103, 1222-6	9.7	77
16	Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. *Journal of Clinical Oncology* , **2010**, 28, 3167-75	2.2	2163
15	Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells. *Journal of Molecular Biology*, **2010**, 399, 596-603	6.5	29
14	Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 12073-8	11.5	79
13	Tumor-associated MHC II-restricted phosphopeptides: New targets for immune recognition. *FASEB Journal*, **2008**, 22, 1079.1	0.9	1
12	Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor. *Nature Immunology*, **2007**, 8, 398-408	19.1	78
11	Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. *Journal of Immunotherapy*, **2007**, 30, 825-30	5	564

10	Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. *Journal of Clinical Oncology*, **2006**, 24, 2283-9	2.2	691
9	Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. *Clinical Cancer Research*, **2006**, 12, 2526-37	12.9	47
8	Cancer regression in patients after transfer of genetically engineered lymphocytes. *Science*, **2006**, 314, 126-9	33.3	2001
7	Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. *Journal of Immunotherapy*, **2006**, 29, 455-63	5	222
6	Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. *Journal of Immunotherapy*, **2005**, 28, 593-8	5	285
5	Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. *Journal of Clinical Oncology*, **2005**, 23, 6043-53	2.2	880
4	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 8372-7	11.5	1325
3	A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma. *Journal of Immunotherapy*, **2002**, 25, 243-251	5	297
2	A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. *Journal of Immunotherapy*, **2002**, 25, 243-51	5	120
1	The role of CD4+ T cell responses in antitumor immunity. *Current Opinion in Immunology*, **1998**, 10, 588-94	7.8	531